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P16-Ki67-HMB45 Immunohistochemical Profiling May
Help Discriminate Between Spitzoid Melanoma and Atypical Spitz Nevi
Robert Garola, MD and Vivekanand Singh, MD

Background
When Spitz nevi have increased vertical thickness (>1.5 MM), show
ulceration and deep seated mitosis, the differential diagnostic considerations
of atypical Spitz nevus (ASN) or a Spitzoid melanoma (SM) enter into
consideration. While expert consultation from a dermatopathologist is most
often sought to resolve the differential diagnosis, it could be expensive and
time consuming. Recently, the use of molecular genetic testing has also
been advocated in the work group up of atypical melanocytic proliferations.
On the contrary, immunohistochemistry is a more routinely used technique in
most pathology centers may be more simple to apply. A single
immunohistochemical marker may not be accurate enough to differentiate
benign from malignant melanocytic lesions. Recently, one study (Ref. 1)
employed the combination of p16, Ki-67 and HMB45 (PKH)
immunohistochemistry on adult melanomas and proposed a combination of
the three markers with scoring in discriminating SM and ASN in children. In
this study we applied the methodology of the published study to atypical
Spitzoid lesions and Spitzoid melanomas.

Methods
• Institutional review board approval was obtained for this HIPAA-compliant
study.
• We retrospectively reviewed 10 cases (4 SM and 6 ASN) from children
(age range 1.5-12 years, 6 females and 4 males).
• H&E stained slides and immunohistochemical stains for PKH were
independently interpreted by two pathologists.
• The extent of IHC expression in the lesional cells were scored following
published criteria comprised as follows:
-P16 scored as 0; >50% stained cells, 1; 11-50%, 2; 1-10%, 3; 0%
-Ki-67 scored as 0; <2%, 1; 2-5%, 2; 6-10%, 3; 11-20%, 4; >20%
-HMB45 scored as 0; gradient present, 1, doubtful/inconclusive
gradient, 2; gradient absent
-The total PKH score for the combination of the 3 antibodies for
any case could vary from 0 to 9.

Results
• Four cases of SM had total PKH scores: 7, 6, 7
and 5.
• Six cases of ASN had PKH scores of 3, 2, 3, 2,
3 and 3.
• In our study all cases of SM had a total score of
>4 and all ASN scored <4.
• HMB45 was completely negative in one case
each of SM and ASN.
• Where aCGH was done, heterozygous loss of
9p correlated well with low P16 immunostain
positive cell numbers in one case.
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Conclusions
1) Our study replicates the findings of the published study of adult
melanomas and nevi that showed a total PKH score of equal/or>4 is
seen in melanoma.
2) A single immunostain could be misleading as Ki-67 labeling index
tended to be higher in young children (<2 years of age) and HMB45
was occasionally negative in both ASN and SM, and P16 could be
completely lost in ASN.
3) We suggest routine use of PKH immunohistochemistry in the work up
of atypical Spitzoid lesions in children.

References
1) Uguen, A., et al. A p16-Ki-HMB45 immunohistochemistry scoring
system as an ancillary diagnostic tool in the diagnosis of melanoma.
Diag Pathol 2015; 10: 195-1005.

Acknowledgement: Joan Whiting HT (ASCP), QIHC for the IHC,
Jeanene Ray (Administrative Coordinator) and Erica Maddock
(Administrative Assistant III) for preparing the poster.

